antifibrinolytic
Sign in to saveAlso known as Antifibrinolytic Agents, Antifibrinolysins, Antifibrinolytics
Antifibrinolytics are a class of medication that are inhibitors of fibrinolysis. Examples include aminocaproic acid (ε-aminocaproic acid) and tranexamic acid. These lysine-like drugs interfere with the formation of the fibrinolytic enzyme plasmin from its precursor plasminogen by plasminogen activators (primarily t-PA and u-PA) which takes place mainly in lysine rich areas on the surface of fibrin.
In the Vinony graph
Vinony's link graph records 186 inbound references to antifibrinolytic, and connects out to coagulation factor IX, blood and bone.
It is catalogued under topics including Antifibrinolytics and Transfusion medicine.
Vinony links it to 11 Wikipedia language editions.
Research
42,734 papers- Antifibrinolytic and Adjunct Hemostatic Agents: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2024
- Antifibrinolytic agents for paediatric scoliosis surgery: a systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2019
- Antifibrinolytic drugs for acute traumatic injury.The Cochrane database of systematic reviews · 2015
- Antifibrinolytic Agents in Plastic Surgery: Current Practices and Future Directions.Plastic and reconstructive surgery · 2018
- Antifibrinolytic therapy to reduce haemoptysis from any cause.The Cochrane database of systematic reviews · 2016
via PubMed
Wikidata facts
Show 2 more facts
- topic's main category
- Category:Antifibrinolytics
- Commons category
- Antifibrinolytics
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Antifibrinolytics are a class of medication that are inhibitors of fibrinolysis. Examples include aminocaproic acid (ε-aminocaproic acid) and tranexamic acid. These lysine-like drugs interfere with the formation of the fibrinolytic enzyme plasmin from its precursor plasminogen by plasminogen activators (primarily t-PA and u-PA) which takes place mainly in lysine rich areas on the surface of fibrin.
Another example, aprotinin, is a naturally occurring broad-spectrum protease inhibitor; some countries refuse to approve this medication because it supposedly has a greater mortality rate than its alternatives (tranexamic acid and aminocaproic acid) and causes damage to the kidneys and heart. It is widely agreed that systemic aprotinin use should be minimized due to these concerns.
Excerpted from Wikipedia’s “antifibrinolytic” article, available under the CC BY-SA 4.0 licence.
Available in 11 languages
via Wikidata sitelinks · CC0